• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk profiles of prostate cancers identified from UK primary care using national referral guidelines.基于国家转诊指南,从英国初级保健中识别的前列腺癌风险概况。
Br J Cancer. 2012 Jan 31;106(3):436-9. doi: 10.1038/bjc.2011.596. Epub 2012 Jan 12.
2
Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.英国基于人群的前列腺特异性抗原检测导致前列腺癌的分期迁移。
BJU Int. 2009 Dec;104(11):1592-8. doi: 10.1111/j.1464-410X.2009.08652.x. Epub 2009 Jun 19.
3
The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.前列腺特异性抗原检测率的提高并未影响英国一个市中心城区人群中前列腺癌的表现。
BJU Int. 2006 Feb;97(2):266-9. doi: 10.1111/j.1464-410X.2005.06011.x.
4
Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center.2007年至2013年间确诊为前列腺癌患者的临床特征及初步治疗:来自丹麦一家初级转诊中心的情况
Acta Oncol. 2016 Dec;55(12):1456-1460. doi: 10.1080/0284186X.2016.1191667. Epub 2016 Jun 22.
5
Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.多参数 MRI 提高经直肠超声引导前列腺活检单独诊断前列腺癌的检出率:PROMIS 研究。
Health Technol Assess. 2018 Jul;22(39):1-176. doi: 10.3310/hta22390.
6
Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.多模态早期检测项目中检测出的前列腺癌的特征。美国癌症协会-国家前列腺癌检测项目的研究人员。
Cancer. 1993 Sep 1;72(5):1701-8. doi: 10.1002/1097-0142(19930901)72:5<1701::aid-cncr2820720534>3.0.co;2-e.
7
Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.新发转移性前列腺癌男性患者的发病率和 5 年死亡率趋势:基于 2 个全国队列的人群分析。
Cancer. 2018 Jul 15;124(14):2931-2938. doi: 10.1002/cncr.31384. Epub 2018 May 3.
8
The effect of direct referral for fast CT scan in early lung cancer detection in general practice. A clinical, cluster-randomised trial.在全科医疗中,直接转诊进行快速CT扫描对早期肺癌检测的效果。一项临床、整群随机试验。
Dan Med J. 2015 Mar;62(3).
9
Metastatic prostate cancer incidence in Australia after amendment to prostate-specific antigen screening guidelines.澳大利亚前列腺特异性抗原筛查指南修订后转移性前列腺癌的发病率
ANZ J Surg. 2018 Jul-Aug;88(7-8):E589-E593. doi: 10.1111/ans.14275. Epub 2017 Nov 30.
10
Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry.前列腺癌的初始管理:挪威国家前列腺癌登记处的首年经验。
BJU Int. 2010 Mar;105(6):805-11; discussion 811. doi: 10.1111/j.1464-410X.2009.08834.x. Epub 2009 Sep 4.

引用本文的文献

1
The efficacy of different biomarkers and endpoints to refine referrals for suspected prostate cancer: the TARGET study (Tiered integrAted tests for eaRly diaGnosis of clinically significant ProstatE Tumours).不同生物标志物和终点在改善疑似前列腺癌转介中的效果:TARGET 研究(分层综合检测以早期诊断有临床意义的前列腺肿瘤)。
BMC Med. 2024 Oct 8;22(1):440. doi: 10.1186/s12916-024-03667-7.
2
Ultrasound/MRI-targeted biopsy versus saturated trans-rectal ultrasound guided biopsy of prostate in patients with primary negative conventional biopsy and still elevated PSA: a prospective randomized clinical trial.对于初次常规活检结果为阴性但前列腺特异性抗原(PSA)仍升高的患者,超声/磁共振成像(MRI)引导下靶向活检与饱和经直肠超声引导下前列腺活检的比较:一项前瞻性随机临床试验
Am J Clin Exp Urol. 2023 Aug 15;11(4):312-319. eCollection 2023.
3
Foggia Prostate Cancer Risk Calculator 2.0: A Novel Risk Calculator including MRI and Bladder Outlet Obstruction Parameters to Reduce Unnecessary Biopsies.福贾前列腺癌风险计算器 2.0:一种新型风险计算器,包含 MRI 和膀胱出口梗阻参数,以减少不必要的活检。
Int J Mol Sci. 2023 Jan 26;24(3):2449. doi: 10.3390/ijms24032449.
4
A prospective multi-center randomized comparative trial evaluating outcomes of transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, mpMRI-targeted 12-core biopsy, and artificial intelligence ultrasound of prostate (AIUSP) 6-core targeted biopsy for prostate cancer diagnosis.一项前瞻性多中心随机对照试验,评估经直肠超声(TRUS)引导下的12针系统活检、磁共振成像(mpMRI)靶向12针活检以及人工智能前列腺超声(AIUSP)6针靶向活检在前列腺癌诊断中的效果。
World J Urol. 2023 Mar;41(3):653-662. doi: 10.1007/s00345-022-04086-0. Epub 2022 Jul 19.
5
Prostate Cancer: Early Detection and Assessing Clinical Risk Using Deep Machine Learning of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data.前列腺癌:利用外周血高维流式细胞术表型数据的深度学习技术进行早期检测和临床风险评估。
Front Immunol. 2021 Dec 16;12:786828. doi: 10.3389/fimmu.2021.786828. eCollection 2021.
6
Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy.作为一种新型血清生物标志物的 Pentraxin-3 对计划进行前列腺活检的患者预测前列腺癌风险的前瞻性验证
Cancers (Basel). 2021 Mar 31;13(7):1611. doi: 10.3390/cancers13071611.
7
External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers.科米奥诺格拉姆预测所有前列腺癌和临床显著前列腺癌的外部验证。
World J Urol. 2020 Oct;38(10):2555-2561. doi: 10.1007/s00345-019-03058-1. Epub 2020 Jan 6.
8
Pixel Prostate Software as a Reliable Tool in Depicting Spatial Distribution and Determination of the Prostate Cancer Volume.像素前列腺软件作为描绘前列腺癌空间分布和确定其体积的可靠工具。
Acta Inform Med. 2019 Jun;27(2):89-95. doi: 10.5455/aim.2019.27.89-95.
9
Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy.基于良性前列腺梗阻相关参数的新型列线图的开发与内部验证,以预测首次前列腺穿刺活检时前列腺癌的风险。
Front Oncol. 2018 Oct 16;8:438. doi: 10.3389/fonc.2018.00438. eCollection 2018.
10
Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.ST6GALNAC3 和 ZNF660 启动子超甲基化在前列腺癌组织和液体活检中的生物标志物潜力。
Mol Oncol. 2018 Apr;12(4):545-560. doi: 10.1002/1878-0261.12183. Epub 2018 Mar 13.

本文引用的文献

1
Randomised prostate cancer screening trial: 20 year follow-up.随机前列腺癌筛查试验:20 年随访。
BMJ. 2011 Mar 31;342:d1539. doi: 10.1136/bmj.d1539.
2
Does the two-week rule pathway improve the diagnosis of soft tissue sarcoma? A retrospective review of referral patterns and outcomes over five years in a regional sarcoma centre.两周规则路径是否能改善软组织肉瘤的诊断?对某地区肉瘤中心五年内的转诊模式和结果进行的回顾性研究。
Ann R Coll Surg Engl. 2010 Jul;92(5):417-21. doi: 10.1308/003588410X12664192075972. Epub 2010 May 19.
3
Screening for prostate cancer remains controversial.前列腺癌筛查仍然存在争议。
Lancet. 2009 Oct 31;374(9700):1482-3. doi: 10.1016/S0140-6736(09)61085-0. Epub 2009 Aug 5.
4
An audit of urology two-week wait referrals in a large teaching hospital in England.对英国一家大型教学医院泌尿外科两周等待转诊情况的审计。
Ann R Coll Surg Engl. 2009 May;91(4):310-2. doi: 10.1308/003588409X391767. Epub 2009 Apr 2.
5
Screening and prostate-cancer mortality in a randomized European study.一项欧洲随机研究中的筛查与前列腺癌死亡率
N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.
6
Mortality results from a randomized prostate-cancer screening trial.一项前列腺癌随机筛查试验的死亡率结果。
N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18.
7
The '2-week wait' rule for referrals for suspected urological cancers--urgent need for refinement of criteria.疑似泌尿系统癌症转诊的“两周等待”规则——迫切需要完善标准。
Ann R Coll Surg Engl. 2008 Sep;90(6):517-22. doi: 10.1308/003588408X301082.
8
The 2-week rule for suspected head and neck cancer in the United Kingdom: referral patterns, diagnostic efficacy of the guidelines and compliance.英国疑似头颈癌的两周就诊原则:转诊模式、指南的诊断效能及依从性
Oral Oncol. 2008 Sep;44(9):851-6. doi: 10.1016/j.oraloncology.2007.10.010. Epub 2008 Jan 29.
9
Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes.肺癌、结直肠癌、前列腺癌和卵巢癌的分期、生存率及延误情况:不同诊断途径的比较
Br J Gen Pract. 2007 Mar;57(536):212-9.
10
Urgent GP referrals for suspected lung, colorectal, prostate and ovarian cancer.因疑似肺癌、结直肠癌、前列腺癌和卵巢癌而由全科医生进行的紧急转诊。
Br J Gen Pract. 2006 May;56(526):355-62.

基于国家转诊指南,从英国初级保健中识别的前列腺癌风险概况。

Risk profiles of prostate cancers identified from UK primary care using national referral guidelines.

机构信息

Department of Urology, Addenbrookes Hospital, Hills Road, Cambridge CB2 0XZ, UK.

出版信息

Br J Cancer. 2012 Jan 31;106(3):436-9. doi: 10.1038/bjc.2011.596. Epub 2012 Jan 12.

DOI:10.1038/bjc.2011.596
PMID:22240787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3273344/
Abstract

OBJECTIVE

Prostate cancer in the United Kingdom is mainly diagnosed from primary care referrals based on national guidelines published by the Department of Health. Here we investigated the characteristics of cancers detected through the use of these guidelines.

METHODS

A prospective two-centre study was established to assess men referred from the primary care based on the UK national guidelines.

RESULTS

The overall cancer detection rate was 43% (169 out of 397) with 15% (26 out of 169) of all cancers metastatic at presentation. Amongst 50-69-year-old men these rates were 34% (68 out of 200) and 15% (10 out of 68). Only 21% (25 out of 123) of men with local cancers had low-risk disease. In comparison to a historical cohort from 2001 (n=137) we found no overall differences in rates of metastatic disease, locally advanced tumours, or risk categories. Amongst 50-69-year-old men with local disease, however, we observed an increase in detection of low-risk cancers in a contemporary cohort (P=0.04). This was primarily because of the increased detection of low-stage organ-confined tumours in this group (P=0.02).

CONCLUSION

Use of the UK prostate cancer guidelines detects a high proportion of clinically significant cancers. Use of the guidelines does not seem to have led to an overall change in the clinical characteristics of presenting cancers. There may, however, be a specific benefit in detecting more low-risk disease in younger men.

摘要

目的

英国的前列腺癌主要根据卫生部发布的国家指南,从初级保健转介中诊断出来。在此,我们研究了通过使用这些指南检测到的癌症的特征。

方法

建立了一项前瞻性的双中心研究,以评估根据英国国家指南从初级保健转介的男性。

结果

总体癌症检出率为 43%(169 例中有 169 例),所有癌症中有 15%(26 例中有 169 例)在就诊时已转移。在 50-69 岁的男性中,这些比例为 34%(200 例中有 68 例)和 15%(68 例中有 10 例)。只有 21%(123 例中有 25 例)的局部癌症患者患有低危疾病。与 2001 年的历史队列(n=137)相比,我们没有发现转移性疾病、局部晚期肿瘤或风险类别方面的总体差异。然而,在患有局部疾病的 50-69 岁男性中,我们观察到当代队列中低危癌症的检出率有所增加(P=0.04)。这主要是因为该组中低分期的器官局限肿瘤的检出率增加(P=0.02)。

结论

使用英国前列腺癌指南可以检测到很大比例的具有临床意义的癌症。使用这些指南似乎并没有导致就诊癌症的临床特征发生总体变化。然而,在年轻男性中,可能有特定的益处可以检测到更多的低危疾病。